InsiderTrades.com logo

NBY Insider Trading

Insider Ownership Percentage: 43.80%
Insider Buying (Last 12 Months): $45,937.40
Insider Selling (Last 12 Months): $0.00

NovaBay Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at NovaBay Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

NovaBay Pharmaceuticals Share Price & Price History

Current Price: $1.53
Price Change: ▲ Price Increase of +0.11 (7.75%)
As of 03/26/2026 05:10 PM ET

This chart shows the closing price history over time for NBY up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

NovaBay Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/8/2025Poplar Point Capital PartnersMajor ShareholderBuy60$2.35$141.00204,060View SEC Filing Icon  
4/4/2025Poplar Point Capital PartnersMajor ShareholderBuy907$2.60$2,358.20204,000View SEC Filing Icon  
4/2/2025Poplar Point Capital PartnersMajor ShareholderBuy183$2.90$530.70198,497View SEC Filing Icon  
3/31/2025Poplar Point Capital PartnersMajor ShareholderBuy4,330$2.95$12,773.50194,330View SEC Filing Icon  
3/28/2025Poplar Point Capital PartnersMajor ShareholderBuy9,880$3.05$30,134.00190,000View SEC Filing Icon  
3/26/2025Poplar Point Capital PartnersMajor ShareholderBuy2,658$3.05$8,106.90176,299View SEC Filing Icon  
3/24/2025Poplar Point Capital PartnersMajor ShareholderBuy20$3.00$60.00169,113View SEC Filing Icon  
3/20/2025Poplar Point Capital PartnersMajor ShareholderBuy1,064$3.05$3,245.20167,819View SEC Filing Icon  
3/18/2025Poplar Point Capital PartnersMajor ShareholderBuy2,800$3.15$8,820.00166,455View SEC Filing Icon  
3/14/2025Poplar Point Capital PartnersMajor ShareholderBuy5,102$3.15$16,071.30161,655View SEC Filing Icon  
3/12/2025Poplar Point Capital PartnersMajor ShareholderBuy2,367$3.10$7,337.70156,546View SEC Filing Icon  
3/10/2025Poplar Point Capital PartnersMajor ShareholderBuy2,929$2.90$8,494.10153,749View SEC Filing Icon  
3/7/2025Poplar Point Capital PartnersMajor ShareholderBuy20$2.75$55.00150,820View SEC Filing Icon  
3/4/2025Poplar Point Capital PartnersMajor ShareholderBuy800$2.90$2,320.00150,800View SEC Filing Icon  
2/27/2025Poplar Point Capital PartnersMajor ShareholderBuy77$3.05$234.85147,378View SEC Filing Icon  
2/25/2025Poplar Point Capital PartnersMajor ShareholderBuy5,006$3.10$15,518.60146,041View SEC Filing Icon  
2/20/2025Poplar Point Capital PartnersMajor ShareholderBuy367$3.15$1,156.05140,944View SEC Filing Icon  
2/18/2025Poplar Point Capital PartnersMajor ShareholderBuy644$3.30$2,125.20130,644View SEC Filing Icon  
2/3/2025Poplar Point Capital PartnersMajor ShareholderBuy519$3.20$1,660.80124,656View SEC Filing Icon  
1/31/2025Poplar Point Capital PartnersMajor ShareholderBuy14,137$3.25$45,945.25124,137View SEC Filing Icon  
1/27/2025Poplar Point Capital PartnersMajor ShareholderBuy6,340$3.45$21,873.00110,000View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)

23.25% of NovaBay Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at NBY by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

NovaBay Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/17/2026ExodusPoint Capital Management LP20,160$0.11M0.0%N/A0.016%Search for SEC Filing on Google Icon
2/16/2026OMERS ADMINISTRATION Corp21,200$0.12M0.0%N/A0.016%Search for SEC Filing on Google Icon
2/13/2026Charles Schwab Investment Management Inc.93,261$0.53M0.0%N/A0.072%Search for SEC Filing on Google Icon
2/13/2026State Street Corp313,703$1.77M0.0%+970.5%0.242%Search for SEC Filing on Google Icon
2/12/2026Jane Street Group LLC70,070$0.40M0.0%N/A0.056%Search for SEC Filing on Google Icon
2/10/2026Goldman Sachs Group Inc.104,341$0.59M0.0%N/A0.083%Search for SEC Filing on Google Icon
2/9/2026Geode Capital Management LLC1,257,705$7.10M0.0%+2,331.7%0.998%Search for SEC Filing on Google Icon
1/21/2026C2C Wealth Management LLC45,000$0.25M0.2%N/A0.036%Search for SEC Filing on Google Icon
11/6/2025Ground Swell Capital LLC19,158$25K0.1%N/A0.319%Search for SEC Filing on Google Icon
10/17/2025Apollon Wealth Management LLC27,561$35K0.0%N/A0.459%Search for SEC Filing on Google Icon
7/17/2025C2C Wealth Management LLC98,000$57K0.1%+78.2%1.685%Search for SEC Filing on Google Icon
2/13/2024Armistice Capital LLC718,768$0.15M0.0%N/A11.007%Search for SEC Filing on Google Icon
11/14/2022Altium Capital Management LP1,095,957$0.12M0.0%N/A1.686%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
NovaBay Pharmaceuticals logo
NovaBay Pharmaceuticals, Inc. develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health. The company also provides wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. It sells its products through the company's web stores, third-party online retailers and distribution partners. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Read More on NovaBay Pharmaceuticals

Today's Range

Now: $1.53
Low: $1.43
High: $1.70

50 Day Range

MA: $8.13
Low: $1.16
High: $73.85

52 Week Range

Now: $1.53
Low: $1.11
High: $99.75

Volume

362,481 shs

Average Volume

692,959 shs

Market Capitalization

$40.73 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.25

Who are the company insiders with the largest holdings of NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals' top insider investors include:
  1. Pharma (Hong Kong) Co Pioneer (Major Shareholder)
  2. Jian Ping Fu (Major Shareholder)
  3. Poplar Point Capital Partners (Major Shareholder)
  4. Jeffrey Kunin (Insider)
  5. Justin Hall (CEO)
  6. Mijia Wu (Director)
  7. Andrew D Jones (CFO)
  8. Area Pioneer Pharma Co Naqu (Major Shareholder)
  9. Audrey Kunin (Insider)
  10. Claude Dufresne (Director)
Learn More about top insider investors at NovaBay Pharmaceuticals.

Who are the major institutional investors of NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals' top institutional investors include:
  1. Geode Capital Management LLC — 1.00%
  2. State Street Corp — 0.24%
  3. Goldman Sachs Group Inc. — 0.08%
  4. Charles Schwab Investment Management Inc. — 0.07%
  5. Jane Street Group LLC — 0.06%
  6. C2C Wealth Management LLC — 0.04%
Learn More about top institutional investors of NovaBay Pharmaceuticals stock.

Which institutional investors are buying NovaBay Pharmaceuticals stock?

During the previous quarter, NBY stock was bought by institutional investors including:
  1. Geode Capital Management LLC
  2. State Street Corp
  3. Goldman Sachs Group Inc.
  4. Charles Schwab Investment Management Inc.
  5. Jane Street Group LLC
  6. C2C Wealth Management LLC
  7. OMERS ADMINISTRATION Corp
  8. ExodusPoint Capital Management LP